ASCO 2022 | Assessing elacestrant in ctDNA-positive patients with ER+ breast cancer

Thomas Meyskens, MD, PhD, EORTCKU Leuven, Leuven, Belgium, describes the rationale and study design of a trial that will assess elacestrant in circulating tumor DNA (ctDNA)-positive patients with ER+ breast cancer. The Phase III EMERALD trial (NCT0377893) has demonstrated the efficacy of elacestrant in breast cancer and the new trial will involve a randomized cohort of ctDNA-positive patients receiving the oral SERD. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.